Camrelizumab plus rivoceranib superior to sorafenib for treatment of unresectable hepatocellular carcinoma
1. Patients in the camrelizumab-rivoceranib group reported significantly greater progression-free survival than the sorafenib group. 2. Treatment-related deaths were comparable ...